Patents by Inventor Svante Hermodsson

Svante Hermodsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060079510
    Abstract: Method and composition for protecting tumorcidal lymphocytes including cytotoxic lymphocytes and NK cells from apoptosis and down regulation are provided. The method and composition include the administration of an effective amount of a PARP-1 inhibitor to a population of cytotoxic T lymphocytes and NK cells in the presence of monocytes or macrophages. In some embodiments, the method and composition additionally include the administration of a reactive oxygen metabolite (ROM) production or release inhibitory compound. Methods of treating cancer, viral diseases, and inflammatory diseases with a PARP-1 inhibitor are likewise provided.
    Type: Application
    Filed: September 29, 2005
    Publication date: April 13, 2006
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Fredrik Thoren, Ana Romero
  • Publication number: 20040219153
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Application
    Filed: June 2, 2004
    Publication date: November 4, 2004
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20040191239
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: April 7, 2004
    Publication date: September 30, 2004
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20040120926
    Abstract: Compositions and methods for treating a variety of conditions in which a reactive oxygen metabolite (ROM) inhibitor or scavenger is administered alone or in conjunction with additional agents. Such conditions include, cancer, viral diseases, and inflammatory diseases, for example.
    Type: Application
    Filed: October 7, 2003
    Publication date: June 24, 2004
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6730692
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: May 4, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6613788
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity and for elevating histamine levels in individuals in need thereof. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 2, 2003
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20030039628
    Abstract: The present invention relates to a method for facilitating activation of T-cells in a patient, comprising: identifying a patient in need of enhanced T-cell activity, administering an effective amount of a T-cell activating composition to the patient, and administering an effective amount of a compound that inhibits the production or release of intercellular reactive oxygen metabolites (ROM) to the patient. The present invention further relates to the use of H2-receptor agonists to augment the effectiveness of vaccines.
    Type: Application
    Filed: October 3, 2002
    Publication date: February 27, 2003
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20030017145
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: September 19, 2002
    Publication date: January 23, 2003
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6498181
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: December 24, 2002
    Assignee: Maxim Pharmaceuticals
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20020193416
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Application
    Filed: August 9, 2002
    Publication date: December 19, 2002
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20020150565
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: June 11, 2002
    Publication date: October 17, 2002
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6462067
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: October 8, 2002
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6407133
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various infectious disease states or pathologies. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: June 18, 2002
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020035998
    Abstract: In a method of treating a viral infection involving activation of NK cells, the improvement comprising administering to a patient receiving such treatment an effective NK-cell-activity facilitating amount of a histamine H2 or 5-HT1A receptor agonist.
    Type: Application
    Filed: October 9, 2001
    Publication date: March 28, 2002
    Inventors: Kristoffer Hellstrand, Svante Hermodsson
  • Patent number: 6305380
    Abstract: In a method of treating a viral infection involving activation of NK cells, the improvement comprising administering to a patient receiving such treatment an effective NK-cell-activity facilitating amount of a histamine H2 or 5-HT1A receptor agonist.
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: October 23, 2001
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20010023256
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: April 12, 2001
    Publication date: September 20, 2001
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6242473
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: June 5, 2001
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6221893
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: April 24, 2001
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6155266
    Abstract: Method for treatment of cancer and infectious disease comprises administering a first composition containing interferon-.alpha. or analogues thereof, together with a second composition containing at least one substance with H.sub.2, or 5-HT.sub.1A, receptor agonist activity, for example, histamine or serotonin. The first and second compositions are either mixed in a preparation or furnished in separate doses.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: December 5, 2000
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson
  • Patent number: 6071942
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity and for elevating histamine levels in individuals in need thereof. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: June 6, 2000
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen